Oral ciprofloxacin effective against modern plague
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Data support use of oral ciprofloxacin for human plague, especially in rural, resource-poor areas.
Why this matters
In vitro, and now in vivo, evidence demonstrate ciprofloxacin has comparable and/or superior bactericidal activity, respectively, against intracellular Yersinia pestis vs streptomycin and doxycycline/gentamicin, giving clinicians another option to treat modern plague.
5 patients enrolled: 4, bubonic plague, confirmed by Y pestis isolated from bubo aspirate or blood cultures; 1, pneumonic plague, characterized by hemoptysis, patchy bilateral infiltrates on chest radiograph, confirmed by Y pestis in sputum.
In addition to ciprofloxacin, all patients (3 admitted, 2 outpatient) also received adjunctive acetaminophen; 2 received a bolus of normal saline.
5/5 became afebrile ≤2 d and were discharged and/or returned to normal activity at day 14.